Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults aged over 18 years.

GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.1 at the end of 2023 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...

GSK’s Arexvy has received expanded approval in Canada for preventing RSV-related lower respiratory tract disease in adults ...

with weakening demand for the Covid-19 products, Pfizer has touted Abrysvo as one of the primary revenue driver. Abrysvo’s main competitor is GSK’s Arexvy, which is approved in the same ...

Pfizer gave little information ... this morning that Arexvy had helped the group deliver an “excellent performance” in 2023, adding that it is planning at least 12 major product launches ...

The content of this article is provided for information purposes only and is ... So the pipeline is strengthening. The Arexvy development is disappointing for GSK shareholders, as it seemed ...

Airbus chief executive Guillaume Faury said the company had “strong demand” across its product range in the first nine months ...

Following outlays for sites in the UK and Belgium earlier this year, GSK is planning to invest up to $800m in the US to double the size and capacity of its site in Marietta, Pennsylvania.

In the realm of product development, GSK revealed new data indicating sustained efficacy over three respiratory syncytial virus (RSV) seasons of its AREXVY vaccine in adults ... and reviewed by an ...